Eleven-month SARS-CoV-2 binding antibody decay, and associated factors, among mRNA vaccinees: implications for booster vaccination
Open Access
- 1 November 2023
- journal article
- research article
- Published by Microbiology Society in Access Microbiology
- Vol. 5 (11) , 000678.v3
Abstract
Background. We examined the 11 month longitudinal antibody decay among two-dose mRNA vaccinees, and identified factors associated with faster decay. Methods. The study included samples from the COVID-19 Occupational Risk, Seroprevalence and Immunity among Paramedics (CORSIP) longitudinal observational study of paramedics in Canada. Participants were included if they had received two mRNA vaccines without prior SARS-CoV-2 infection and provided two blood samples post-vaccination. The outcomes of interest were quantitative SARS-CoV-2 antibody concentrations. We employed spaghetti and scatter plots (with kernel-weighted local polynomial smoothing curve) to describe the trend of the antibody decay over 11 months post-vaccine and fit a mixed effect exponential decay model to examine the loss of immunogenicity and factors associated with antibody waning over time. Results. This analysis included 652 blood samples from 326 adult paramedics. Total anti-spike antibody levels peaked on the twenty-first day (antibody level 9042 U ml−1) after the second mRNA vaccine dose. Total anti-spike antibody levels declined thereafter, with a half-life of 94 [95 % CI: 70, 143] days, with levels plateauing at 295 days (antibody level 1021 U ml−1). Older age, vaccine dosing interval Conclusion. Antibody levels declined after the initial mRNA series with a half-life of 94 days, plateauing at 295 days. These findings may inform the timing of booster vaccine doses and identifying individuals with faster antibody decay.Keywords
All Related Versions
Funding Information
- Government of Canada
- Michael Smith Health Research BC
This publication has 36 references indexed in Scilit:
- Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19New England Journal of Medicine, 2021
- Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance dataThe Lancet, 2021
- The kernel-weighted local polynomial regression (KwLPR) approach: an efficient, novel tool for development of QSAR/QSAAR toxicity extrapolation modelsJournal of Cheminformatics, 2021
- A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severityCellular & Molecular Immunology, 2021
- COVID-19-neutralizing antibodies predict disease severity and survivalCell, 2021
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesNew England Journal of Medicine, 2020
- Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparisonThe Lancet Infectious Diseases, 2020
- Long-Term Persistence of IgG Antibodies in SARS-CoV Infected Healthcare WorkersmedRxiv, 2020
- Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus InfectionsEmerging Infectious Diseases, 2019
- Weighted Local Regression and Kernel Methods for Nonparametric Curve FittingJournal of the American Statistical Association, 1987